A newly released diabetes biomarker assay was designed to close the information gap between daily blood glucose testing and the two-three month HbA1c (glycated hemoglobin) reading.

The new Glycated Serum Protein (GSP) LiquiColor assay, which has both [US] Food and Drugs Administration and European CE approval, is manufactured by the EKF Diagnostics (Cardiff, United Kingdom) subsidiary Stanbio Chemistry.

The GSP LiquiColor test is based on a double enzymatic degradation method that utilizes the specificity of fructosyl-amino oxidase to eliminate inaccuracies caused by non-glycated protein reducing substances, which significantly interfere with the NBT fructosamine method. The test is available as a liquid-stable kit with calibrator. It is suitable for use on a variety of clinical chemistry analyzers, with on-board stability of up to four weeks.

“GSP can provide a helpful supplement to glucose and HbA1c testing, when assessing glycemic control for the management of diabetic patients, especially in cases where HbA1c may be inaccurate,” said Al Blanco, business unit director at EKF Diagnostics. “GSP bridges the glycation gap, which is the difference between actual measured HbA1c and predicted HbA1c from glycated serum protein, to provide improved prediction of diabetic complications.”

Related Links:
EKF Diagnostics